INVESTORS

2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/12/16Enumeral Completes Successful Warrant Tender Offer and Receives $3.4 Million in Gross Proceeds
Obtains Consent to Remove Anti-Dilution Protection of Outstanding Warrants and Continues to Deliver on Turnaround Plan CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 12, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and advancement of next generation therapeutics in cancer and other diseases, today announced that the Company has received gross proceeds of approxi... 
Printer Friendly Version
11/10/16Enumeral Reports Third Quarter Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today provided a business update and announced its financial results for the quarter ended September 30, 2016. “Over the last several weeks, we have ... 
Printer Friendly Version
09/22/16Enumeral Appoints Wael Fayad as Chairman, President and Chief Executive Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 22, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that Wael Fayad has been appointed Chairman, President, and Chief Executive Officer of the Company, effective as of September 21, 2016. ... 
Printer Friendly Version
08/12/16Enumeral Reports Second Quarter Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 12, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced its financial results for the quarter ended June 30, 2016. Recent Business Highlights In July 2016, Enumeral sold ... 
Printer Friendly Version
08/01/16Enumeral Announces Sale of 12% Senior Secured Promissory Notes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 1, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that on July 29, 2016 the Company sold 12% Senior Secured Promissory Notes (the “Notes”) in a private placement offering to certain accredited invest... 
Printer Friendly Version
06/06/16Enumeral Receives Maintenance Fee to Continue License Agreement with Pieris and Enters into Definitive License Agreement
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that, as contemplated in the April 18, 2016 License and Transfer Agreement (the “License Agreement”), it has received a $750,000 license maintenance fee ... 
Printer Friendly Version
05/13/16Enumeral Reports First Quarter Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 13, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced its financial results for the three months ended March 31, 2016. Recent Business Highlights In April 2016, Enumeral... 
Printer Friendly Version
04/18/16Enumeral Announces Additional Data on Its Novel Class of PD-1 Antagonist to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it will present research findings on the Company’s novel class of anti-PD-1 antibodies in a poster at the AACR Annual Meeting 2016 in New Orleans. ... 
Printer Friendly Version
04/18/16Enumeral and Pieris Pharmaceuticals Enter into License and Transfer Agreement
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that it has entered into a License and Transfer Agreement (the “License Agreement”) with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH ... 
Printer Friendly Version
03/31/16Enumeral to Present at the 3rd Annual Jefferies Immuno-Oncology Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 31, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral’s President and Chief Executive Officer, will present at the 3rd Annual Jefferies Immuno-Oncology Summit at 3:25 pm Eastern Time in t... 
Printer Friendly Version
03/30/16Enumeral Reports Fourth Quarter and Year-End 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 30, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months and full year ended December 31, 2015. Recent Business Highlights In January 2016, Enume... 
Printer Friendly Version
01/19/16Enumeral to Present at the Noble Financial Capital Markets’ 12th Annual Investor and Equity Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 19, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral’s President and Chief Executive Officer, will present at the Noble Financial Capital Markets’ 12th Annual Investor and Equity Conferen... 
Printer Friendly Version
01/11/16Enumeral and MD Anderson Enter Into Collaborative Research and Development Agreement
Strategic Collaboration Aims to Discover and Develop Potentially Novel Antibodies Against Specified Targets for Immunotherapy CAMBRIDGE, Mass. & HOUSTON, Texas--(BUSINESS WIRE)--Jan. 11, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) today announced that it has entered into a Collaborative Research and Development Agreement with The University of Texas MD Anderson Cancer Center. Scientists from Enumeral and MD Anderson will collab... 
Printer Friendly Version
01/08/16Enumeral Presents Research Results for Novel Class of Anti-PD-1 Antibodies at AACR’s 2016 Tumor Microenvironment Special Conference
Enumeral’s lead humanized anti-PD-1 antibodies demonstrated high levels of T-cell activation in ex vivo human immune cell assays and anti-tumor activity in in vivo studies CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other di... 
Printer Friendly Version
01/06/16Enumeral to Participate in the 2016 East/West CEO Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral’s President and Chief Executive Officer, will participate in the 2016 East/West CEO Conference on the panel ... 
Printer Friendly Version
01/05/16Enumeral to Present at Biotech Showcase 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 5, 2016-- Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral’s President and Chief Executive Officer, will present a corporate overview at Biotech Showcase 2016 on Wednesday, ... 
Printer Friendly Version